唑来膦酸联合GP方案化疗治疗非小细胞肺癌骨转移的疗效及对炎性因子水平的影响  

Efficacy of zoledronic acid combined with GP chemotherapy in the treatment of bone metastases from non-small cell lung cancer and its effect on inflammatory factor levels

作　　者：蒋轶[1] 叶韬[1] Jiang Yi;Ye Tao(The First People's Hospital of Jiujiang City,Jiangxi Province,Jiujiang,Jiangxi,332000,China)

机构地区：[1]江西省九江市第一人民医院,江西九江332000

出　　处：《当代医学》2020年第27期1-3,共3页Contemporary Medicine

基　　金：九江市科技计划项目(2017101)。

摘　　要：目的探讨唑来膦酸联合GP方案化疗治疗非小细胞肺癌骨转移的疗效及对炎性因子水平的影响。方法选取2017年5月至2019年7月就诊于本院的84例非小细胞肺癌骨转移患者,按照随机数字表法分为两组,各42例。对照组使用顺铂+吉西他滨(GP)方案化疗,实验组在对照组基础上加用唑来膦酸注射液治疗。比较两组疼痛缓解、骨转移灶治疗效果、炎性因子水平和治疗安全性。结果实验组疼痛总缓解率为85.71%,高于对照组的42.86%,差异有统计学意义(P<0.05);实验组骨转移灶治疗总有效率为59.52%,高于对照组的21.43%,差异有统计学意义(P<0.05);实验组肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)水平分别为(2.88±0.27)ng/L、(24.30±1.19)μg/L,均低于对照组[(5.42±0.39)ng/L、(36.89±1.98)μg/L],差异有统计学意义(P<0.05);治疗期间两组不良反应发生率比较差异无统计学意义。结论唑来膦酸联合GP方案化疗治疗非小细胞肺癌骨转移可增强镇痛效果,减缓骨转移,降低炎性因子释放,安全性较高,值得临床推广。Objective To investigate the effect of zoledronic acid combined with GP chemotherapy on bone metastases in non-small cell lung cancer and its effect on the level of inflammatory factors.Methods 84 patients with non-small cell lung cancer bone metastases who were treated in our hospital from May 2017 to July 2019 were selected and they were divided into two groups according to the random number table method,with 42 cases in each group.The control group was treated with cisplatin+gemcitabine(GP)regimen.Based on the control group,the experimental group was treated with zoledronic acid injection.The pain relief,bone metastasis treatment effect,inflammatory factor levels,and treatment safety were compared between the two groups.Results The total pain relief rate in the experimental group was 85.71%,which was higher than the control group of 42.86%,and the difference was statistically significant(P<0.05).The total effective rate of bone metastases in the experimental group was 59.52%,which was higher than the control group of 21.43%,the difference was statistically significant(P<0.05).The levels of tumor necrosis factor-α(TNF-α)and interleukin-6(IL-6)in the experimental group were(2.88±0.27)ng/L and(24.30±1.19)μg/L,which were lower than(5.42±0.39)ng/L and(36.89±1.98)μg/L in the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups during treatment.Conclusion Zoledronic acid combined with GP chemotherapy for non-small cell lung cancer bone metastasis can enhance the analgesic effect,slow down bone metastasis,reduce the release of inflammatory factors,and have higher safety.

关 键 词：非小细胞肺癌骨转移 唑来膦酸 GP方案化疗 炎性因子 疼痛缓解 安全性 

分 类 号：R734.2[医药卫生—肿瘤]